Tevogen Bio
Tevogen Bio is a clinical-stage immunotherapy company developing off-the-shelf, genetically unmodified CD8+ T cell therapies using its ExacTcell platform, with lead candidate TVGN-489 targeting COVID-19 and Long COVID, plus the Tevogen.AI drug discovery platform and a diversifying generics and healthcare services initiative.
- Company typePublic
- Founded2020
- HeadquartersWarren, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Tevogen Bio does
Tevogen Bio is a clinical-stage specialty immunotherapy company founded in 2020 and headquartered in Warren, New Jersey, publicly traded on Nasdaq under the ticker TVGN following a February 2024 SPAC business combination with Semper Paratus Acquisition Corporation. The company develops off-the-shelf, genetically unmodified CD8+ cytotoxic T lymphocyte (CTL) therapies using its proprietary ExacTcell platform, targeting infectious diseases (lead product TVGN-489 for COVID-19 and Long COVID in high-risk patients), cancers (EBV-associated leukemias, HPV-related cancers), and neurological disorders (multiple sclerosis via EBV-specific T cells). A published peer-reviewed proof-of-concept trial reported that 100% of treated high-risk COVID-19 patients did not develop Long COVID, and HLA-target expansion now reaches approximately 65% of the U.S. population. The FDA has cleared the IND application for the COVID-19 CTL therapy, and the company holds multiple granted US patents plus international patent applications covering its CTL preparation methods and AI-driven peptide prediction technology.
The company's business model centers on multi-pillar revenue streams all currently pre-commercial: (1) future commercialization of Tevogen cell therapy products through hospital and specialty pharmacy channels upon regulatory approval; (2) Tevogen.AI, an AI-driven drug discovery platform leveraging the PredicTcell machine learning model (trained on 655+ million peptide sequences from 24 million proteins, achieving 92% recall and 48% precision in beta) to offer predictive modeling, co-development, and SaaS-style services to pharmaceutical partners; (3) Tevogen Generics, evaluating acquisition of Apozeal Pharmaceutical and its 11 FDA-approved ANDA products to enter the U.S. generics market; and (4) a healthcare services initiative evaluating MSO and CRO acquisitions targeting approximately $100 million in combined annual revenue. Tevogen.AI operates on Microsoft Azure and Databricks infrastructure with three production AI agents that monitor scientific literature and integrate wet lab results into continuous model improvement. The company had 11-50 employees, insider ownership of 70-74%, FY2025 operating loss of $26.1 million (down 51% YoY), and Q1 2026 loss of $5.4 million (down 48% YoY).
Tevogen Bio firmographics
Firmographics- Name
- Tevogen Bio
- Legal name
- Tevogen Bio, Inc.
- Website
- https://tevogen.com
- Company type
- Public
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Tevogen Bio is a clinical-stage immunotherapy company developing off-the-shelf, genetically unmodified CD8+ T cell therapies using its ExacTcell platform, with lead candidate TVGN-489 targeting COVID-19 and Long COVID, plus the Tevogen.AI drug discovery platform and a diversifying generics and healthcare services initiative.
- Ownership category
- akta.pro rank
Tevogen Bio industry classification
Industry- Product category
- Clinical-Stage Cell Therapy Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industries
- Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)
Keywords
Where Tevogen Bio is headquartered
LocationHeadquarters
- HQ city
- Warren
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Tevogen Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- T Cell Therapy Commercialization: Tevogen plans to commercialize its pipeline of off-the-shelf T cell therapies for infectious diseases, cancers, and neurological disorders. Revenue would come from product sales to healthcare providers and health systems upon regulatory approval.
- AI Platform Services: Tevogen.AI aims to generate revenue through partnerships with pharmaceutical companies for co-development of peptide candidates, licensing of predictive modeling capabilities, and potential SaaS-style access to its PredicTcell platform.
- Healthcare Services Acquisitions: The company is evaluating acquisitions of MSO and CRO organizations that together could represent approximately $100 million in combined annual revenue, operating as subsidiaries.
- Generics Business: Tevogen Generics aims to provide affordable generic pharmaceuticals, potentially including 11 FDA-approved ANDA products pending acquisition of Apozeal Pharmaceutical.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels10 records
Tevogen Bio product offering
Product offeringCore offering
Tevogen Bio is a clinical-stage specialty immunotherapy company developing off-the-shelf, genetically unmodified CD8+ cytotoxic T cell therapies for infectious diseases, cancers, and neurological disorders using its proprietary ExacTcell platform. Its lead investigational product TVGN-489 targets SARS-CoV-2 in high-risk COVID-19 and Long COVID patients, with HLA coverage expanded to approximately 65% of the U.S. population. The company also operates Tevogen.AI, an AI drug discovery initiative using the PredicTcell predictive model trained on more than 655 million peptide sequences to identify immunologically active targets, and is expanding into domestic generics (Tevogen Generics) and healthcare services via MSO/CRO acquisitions.
Product overview
Tevogen Bio is a clinical-stage specialty immunotherapy company operating primarily through its proprietary ExacTcell technology platform for developing off-the-shelf, genetically unmodified CD8+ T cell therapies. The company's lead product TVGN-489 is in clinical development for COVID-19 and Long COVID treatment. Tevogen.AI serves as the AI division powering drug discovery through the PredicTcell predictive model. The company is expanding into generics (Tevogen Generics), healthcare services, and digital health platforms (Clinicus) to diversify revenue streams toward becoming a broader healthcare enterprise.
Differentiator
Problem solved
Functional benefit
Brands
- Tevogen.AI: Artificial intelligence initiative focused on drug development using proprietary predictive technologies including PredicTcell™ machine learning model for identifying immunologically active peptides.
- Tevogen Generics
- Clinicus
Products and services
- TVGN-489 Investigational off-the-shelf, genetically unmodified, allogeneic SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte therapy for the treatment of COVID-19 and Long COVID in high-risk and immunocompromised patients. Expanded HLA coverage reaches approximately 65% of the U.S. population. FDA IND has been cleared.
- Tevogen.AI Artificial intelligence drug discovery platform offered to pharmaceutical companies for AI-driven peptide target identification, co-development of peptide candidates, and licensing or SaaS-style access to the PredicTcell predictive model. Built on Microsoft Azure and Databricks infrastructure.
- Tevogen Generics Business unit focused on affordable generic pharmaceuticals and domestic manufacturing to support pharmaceutical affordability and supply chain resilience, with planned access to 11 FDA-approved ANDA products via the Apozeal Pharmaceutical acquisition.
Quantifiable outcome
- TVGN 489 demonstrated 100% of treated high-risk patients did not develop Long COVID in proof-of-concept data
- +5 more outcomes
Companies that use Tevogen Bio
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles2 records
Tevogen Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
Tevogen Bio partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered supporting and core.
- AvanadesupportingJoint presentation at Microsoft Fabric Community Conference (FabCon 2026) alongside Microsoft executives, exploring agentic AI in data engineering.
- Yale School of Public HealthsupportingPartnership to prepare tomorrow's leaders in regulatory science. Collaboration on public health initiatives and innovation-driven programs.
- BioCentriq (New Jersey Innovation Institute)supportingPartnership with BioCentriq, New Jersey Innovation Institute's cell and gene therapy center, to enhance Tevogen's development capacity of its proprietary targeted T cell therapy for COVID-19.
- MicrosoftcoreCloud and AI partnership with Microsoft for drug development. Tevogen.AI utilizes Azure cloud services and collaborates on Microsoft Fabric for data engineering. Mittul Mehta presented at Microsoft FabCon 2026.
- DatabrickscoreExpanded collaboration with Databricks to build PredicTcell model with focus on oncology. Company commissions Databricks for accelerated development of precision AI tool for target prediction.
- CD8 TechnologysupportingLetter of Intent signed with CD8 Technology to build up to $50 million R&D and manufacturing facility. First phase of manufacturing capacity expansion.
- Sciometrix Inc.supportingNon-binding LOI to evaluate potential majority acquisition of Sciometrix, developer of Clinicus digital care management platform. Would integrate remote patient monitoring with Tevogen.AI.
- Apozeal Pharmaceutical Inc.supportingNon-binding LOI to explore potential acquisition of Apozeal Pharmaceutical, which specializes in affordable medicine development with 11 FDA-approved ANDA products and development pipeline.
- Thomas Jefferson University / Jefferson University HospitalscoreClinical trial partnership for TVGN-489 proof-of-concept trial treating high-risk COVID-19 patients. Principal Investigator Dr. Neal Flomenberg (CSO) previously affiliated with Jefferson.
Scale indicators20 records
Recent moves10 records
Expansion highlights7 records
Tevogen Bio competitors and assessment
Company assessmentBroad incumbents
- Crispr Therapeutics: CRISPR Therapeutics is a leading gene-editing company developing both ex vivo cell therapies (including allogeneic CAR-T) and in vivo gene-editing therapeutics. Comparable to Tevogen in cell therapy modality, though at significantly greater scale and with broader gene-editing capabilities.
Emerging players
- Caribou Biosciences: Caribou Biosciences develops allogeneic CAR-T cell therapies using CRISPR gene editing. Comparable to Tevogen as a smaller, emerging allogeneic cell therapy player addressing oncology with off-the-shelf modalities.
- Recursion Pharmaceuticals: Recursion is a clinical-stage biotech using AI/ML-driven drug discovery. Comparable to Tevogen's Tevogen.AI initiative in leveraging proprietary data assets and machine learning to accelerate pharmaceutical target identification and development.
- Century Therapeutics: Century Therapeutics develops iPSC-derived allogeneic cell therapies for cancer and autoimmune disease. Comparable to Tevogen as a smaller, emerging off-the-shelf cell therapy company with similar target indications.
Direct peers
- Cellectis: Cellectis is a clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies using gene-editing technology. Comparable to Tevogen in pioneering allogeneic T cell approaches and addressing oncology indications with off-the-shelf products.
- Nkarta Therapeutics: Nkarta is developing allogeneic NK cell therapies for cancer. Comparable to Tevogen in pursuing off-the-shelf cell therapy platforms targeting oncology, with shared challenges around manufacturing scale and HLA matching.
- Allogene Therapeutics: Allogene Therapeutics is a clinical-stage immuno-oncology company developing allogeneic CAR-T cell therapies for cancer. It is one of the most direct comparables to Tevogen Bio given its shared allogeneic, off-the-shelf T cell platform strategy and oncology focus.
- Adaptimmune Therapeutics: Adaptimmune develops engineered T cell receptor (TCR) therapies for solid tumors. Comparable to Tevogen in targeting cancers with T cell-based modalities and pursuing off-the-shelf and personalized approaches to cell therapy commercialization.
- Fate Therapeutics: Fate Therapeutics develops off-the-shelf, iPSC-derived NK and T cell therapies for cancer and autoimmune disease. Comparable to Tevogen in pursuing allogeneic, off-the-shelf cell therapies at scale and addressing multiple oncology indications.
- Atara Biotherapeutics: Atara develops allogeneic T cell immunotherapies, including EBV-specific and other viral-associated cancer programs. Highly comparable to Tevogen given its allogeneic CTL platform and EBV/cancer focus that closely mirrors Tevogen's ExacTcell approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Tevogen Bio social profiles
Digital presenceTevogen Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tevogen Bio leadership team
Management profileNumber of profiles
Profiles11 records
Tevogen Bio subsidiaries and ownership
Company hierarchySubsidiaries3 records
Tevogen Bio funding detail
Funding detailFunding overview
Funding rounds10 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tevogen Bio M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tevogen Bio
What does Tevogen Bio do?
Tevogen Bio is a clinical-stage specialty immunotherapy company developing off-the-shelf, genetically unmodified CD8+ cytotoxic T cell therapies for infectious diseases, cancers, and neurological disorders using its proprietary ExacTcell platform. Its lead investigational product TVGN-489 targets SARS-CoV-2 in high-risk COVID-19 and Long COVID patients, with HLA coverage expanded to approximately 65% of the U.S. population. The company also operates Tevogen.AI, an AI drug discovery initiative using the PredicTcell predictive model trained on more than 655 million peptide sequences to identify immunologically active targets, and is expanding into domestic generics (Tevogen Generics) and healthcare services via MSO/CRO acquisitions.
Is Tevogen Bio a public or private company?
Tevogen Bio is a public company. It is classified as public and is currently operating.
When was Tevogen Bio founded?
Tevogen Bio was founded in 2020. It employs 11 to 50 people.
Where is Tevogen Bio based?
Tevogen Bio is headquartered in Warren, United States, in the North America region.
How does Tevogen Bio make money?
Four revenue lines are on record. T Cell Therapy Commercialization is the primary driver. The others are AI Platform Services, healthcare Services Acquisitions and generics Business.
Who are Tevogen Bio's main competitors?
Crispr Therapeutics is listed as a broad incumbent. Emerging players are Caribou Biosciences, Recursion Pharmaceuticals and Century Therapeutics. Direct peers are Cellectis, Nkarta Therapeutics, Allogene Therapeutics, Adaptimmune Therapeutics, Fate Therapeutics and Atara Biotherapeutics.
Does Tevogen Bio have an API?
No public API is recorded for Tevogen Bio.
What industry is Tevogen Bio in?
Tevogen Bio's product category is Clinical-Stage Cell Therapy Immunotherapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2836.